Publications by authors named "Ron Macfarland"

Claim this Profile
D
Design of substituted imidazolidinylpiperidinylbenzoic acids as chemokine receptor 5 antagonists: potent inhibitors of R5 HIV-1 replication.
Renato Skerlj, Gary Bridger, Yuanxi Zhou, Elyse Bourque, Ernest McEachern, Ron Macfarland

J Med Chem· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mitigating hERG Inhibition: Design of Orally Bioavailable CCR5 Antagonists as Potent Inhibitors of R5 HIV-1 Replication.
Renato Skerlj, Gary Bridger, Yuanxi Zhou, Elyse Bourque, Ernest McEachern, Ron MacFarland

ACS Med Chem Lett· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacology of AMD3465: a small molecule antagonist of the chemokine receptor CXCR4.
Veronique Bodart, Virginia Anastassov, Marilyn C Darkes, Stefan R Idzan, Jean Labrecque, Ron T Macfarland

Biochem Pharmacol· October 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Proof of activity with AMD11070, an orally bioavailable inhibitor of CXCR4-tropic HIV type 1.
Graeme Moyle, Edwin DeJesus, Marta Boffito, Rebecca S Wong, Colleen Gibney, Ron MacFarland

Clin Infect Dis· March 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and pharmacodynamics of plerixafor in patients with non-Hodgkin lymphoma and multiple myeloma.
Douglas A Stewart, Clayton Smith, Ron MacFarland, Gary Calandra

Biol Blood Marrow Transplant· January 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase II study of plerixafor (AMD3100) plus G-CSF for autologous hematopoietic progenitor cell mobilization in patients with Hodgkin lymphoma.
Amanda Cashen, Sandra Lopez, Feng Gao, Gary Calandra, Ron MacFarland

Biol Blood Marrow Transplant· November 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of low-dose ritonavir on the pharmacokinetics of the CXCR4 antagonist AMD070 in healthy volunteers.
Ying Jun Cao, Charles W Flexner, Shelia Dunaway, Jeong-Gun Park, Karin Klingman, Ron MacFarland

Antimicrob Agents Chemother· May 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic effect of AMD070, an Oral CXCR4 antagonist, on CYP3A4 and CYP2D6 substrates midazolam and dextromethorphan in healthy volunteers.
Myaing M Nyunt, Stephen Becker, Ron T MacFarland, Priscilla Chee, Robert Scarborough

J Acquir Immune Defic Syndr· April 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multiple-dose escalation study of the safety, pharmacokinetics, and biologic activity of oral AMD070, a selective CXCR4 receptor inhibitor, in human subjects.
Nimalie D Stone, Shelia B Dunaway, Charles Flexner, Camlin Tierney, Gary B Calandra, Ron T MacFarland

Antimicrob Agents Chemother· July 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Durable engraftment of AMD3100-mobilized autologous and allogeneic peripheral-blood mononuclear cells in a canine transplantation model.
Lauri Burroughs, Marco Mielcarek, Marie-Térèse Little, Gary Bridger, Ron Macfarland

Blood· December 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Leukocytosis and Mobilization of CD34+ Hematopoietic Progenitor Cells by AMD3100, a CXCR4 Antagonist.
Kai Hübel, W Conrad Liles, Hal E Broxmeyer, Elin Rodger, Brent Wood, Ron Macfarland

Support Cancer Ther· April 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis